Fulgent Genetics Inc (FLGT)

Debt-to-equity ratio

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Long-term debt US$ in thousands — — — — — — — — — — — — — — — — — — — —
Total stockholders’ equity US$ in thousands 1,133,230 1,138,440 1,132,550 1,129,940 1,136,100 1,258,700 1,259,760 1,268,920 1,269,880 1,281,400 1,304,760 1,312,960 1,165,880 1,036,780 920,725 801,566 569,387 186,955 87,043 81,372
Debt-to-equity ratio 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

December 31, 2024 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $1,133,230K
= 0.00

The debt-to-equity ratio of Fulgent Genetics Inc has remained consistently at 0.00 from March 31, 2020, to December 31, 2024. This indicates that the company has no financial leverage in its capital structure during this period. A debt-to-equity ratio of 0.00 typically suggests that the company is entirely funded by equity, with no debt obligations. While this may indicate a lower risk of financial distress due to debt, it could also suggest missed opportunities for leveraging debt as a cheaper source of financing. The stable trend in the debt-to-equity ratio implies that Fulgent Genetics has maintained a conservative capital structure without taking on additional debt relative to its equity levels over the analyzed period.